KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares Repurchased
Ratios

Gilead Sciences (GILD) Receivables - Net (2016 - 2025)

Gilead Sciences (GILD) has disclosed Receivables - Net for 17 consecutive years, with $4.9 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables - Net fell 7.63% year-over-year to $4.9 billion, compared with a TTM value of $4.9 billion through Dec 2025, down 7.63%, and an annual FY2025 reading of $4.9 billion, up 11.15% over the prior year.
  • Receivables - Net was $4.9 billion for Q4 2025 at Gilead Sciences, down from $5.1 billion in the prior quarter.
  • Across five years, Receivables - Net topped out at $5.6 billion in Q3 2023 and bottomed at $3.8 billion in Q1 2022.
  • Average Receivables - Net over 5 years is $4.8 billion, with a median of $4.8 billion recorded in 2022.
  • The sharpest move saw Receivables - Net soared 53.66% in 2021, then fell 16.1% in 2022.
  • Year by year, Receivables - Net stood at $4.5 billion in 2021, then increased by 6.32% to $4.8 billion in 2022, then decreased by 2.45% to $4.7 billion in 2023, then grew by 14.14% to $5.3 billion in 2024, then decreased by 7.63% to $4.9 billion in 2025.
  • Business Quant data shows Receivables - Net for GILD at $4.9 billion in Q4 2025, $5.1 billion in Q3 2025, and $4.8 billion in Q2 2025.